3 results
Part 1: To assess the safety and effectiveness of subcutaneous golimumab 50 mg (SC-GLM50), administered by autoinjection once monthly during 6 months, when combined with different DMARD regimens used in daily rheumatology. Part 2: In subjects who…
The primary objective of this study is to evaluate the course of plasma- and urinary levels of carnitine and all carnitine esters during the first cycle of treatment with oxaliplatin-based chemotherapy and intravenous carnitine supplementation. The…
The primary objectives are to investigate which determinants (primarily carnitine status) determine the effect of carnitine supplementation on metabolic flexibility and insulin sensitivity in patients with type 2 diabetes. Furthermore, a secondary…